2016 American Transplant Congress
High Efficacy of Ledipasvir/Sofosbuvir with Ribavirin in HCV Genotype-1 Infected Patients with Decompensated Liver Disease: Analysis by MELD Score from the SOLAR-1 and SOLAR-2 Trials.
Introduction: HCV infected patients with decompensated liver disease have significant morbidity & mortality. The efficacy & safety of LDV/SOF + RBV was evaluated in a…2016 American Transplant Congress
Time Course of Hepatic Graft Function Improvement After Ledipasivir/Sofosbuvir Treatment in Liver Transplant Recipients with HCV and Fibrosis or Cirrhosis Who Achieved SVR.
Background: In SOLAR-1, liver transplant recipients with HCV and either fibrosis or cirrhosis were treated at baseline with ledipasvir/sofosbuvir and ribavirin for 12 or 24…2016 American Transplant Congress
Impact of Left Ventricular Diastolic Dysfunction on Patients Being Evaluated for Liver Transplantation.
IntroductionDiastolic dysfunction (DD) is the cardinal finding in cirrhotic cardiomyopathy, a condition in patients with liver disease that is associated with an increased risk of…2015 American Transplant Congress
Estimation of Glomerular Filtration Rate With Serum Cystatin C Accurately Discriminates Renal Dysfunction in Liver Transplant Candidates With End-Stage Liver Disease
Background: Renal insufficiency is common in end-stage liver disease (ESLD) and is linked to survival in patients awaiting liver transplantation. Serum creatinine correlates poorly with…2015 American Transplant Congress
MELD Velocity – An Early Predictor of Increased Mortality Risk
INTRODUCTION: MELD is a satisfactory predictor of 3-month mortality in patients with cirrhosis. However, sub-populations of patients at increased hazard of mortality, but not well…2015 American Transplant Congress
Functional Decline in Liver Transplant Candidates: Results from the Functional Assessment in Liver Transplantation (FrAILT) Study
Background: Cirrhosis is characterized by sarcopenia and malnutrition, leading to progressive functional decline. No studies have objectively measured physical functional decline in cirrhotics awaiting liver…2015 American Transplant Congress
Pre-Transplant Portal Vein Recanalization-Transjugular Intrahepatic Portosystemic Shunt in Patients With Chronic Portal Vein Thrombosis
Northwestern Memorial Hospital, Chicago, IL.
Background: Chronic, occlusive portal vein thrombosis (PVT) associated with cirrhosis represents a relative contraindication to liver transplantation (LT) in some centers. From a surgical perspective,…2015 American Transplant Congress
High Tolerability With Sofosbuvir-Based Direct-Acting Antiviral Therapy in Liver Transplant Recipients With Recurrent Hepatitis C
Background: Reports on efficacy, safety, and tolerability of sofobuvir-based antiviral regimens in liver transplant recipients with recurrent hepatitis C are limited. Methods: We performed a…2015 American Transplant Congress
Hospital Characteristics Mediate Variation in Cirrhosis Mortality in Transplant and Non-Transplant Facilities
Hospitals vary significantly in cirrhosis mortality. We aimed to determine whether hospital structural characteristics mediate this effect.Methods: We used 2009 data from the HCUP Nationwide…2015 American Transplant Congress
Survival Benefit of Simultaneous Liver Kidney (SLK) Transplant in Liver Transplant Candidates With Renal Dysfunction
Survival benefit of SLK over liver transplant alone (LTA) in patients with same level of renal dysfunction and effect of organ quality on mortality are…
American Transplant Congress abstracts